Lung-derived factors mediate breast cancer cell migration through CD44 receptor-ligand interactions in a novel Ex vivo system for analysis of organ-specific soluble proteins

Neoplasia (United States)

Volumn 16, Issue 2, 2014, Pages 180-191

  Chu, Jenny E ^a,b   Xia, Ying ^a   Chin Yee, Benjamin ^a   Goodale, David ^a   Croker, Alysha K ^a,b   Allan, Alison L ^a,b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR; HERMES ANTIGEN; L SELECTIN; OSTEOPONTIN; PADGEM PROTEIN; CD44 PROTEIN, HUMAN; CULTURE MEDIUM; LIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRDU ASSAY; BREAST CANCER; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MICROARRAY; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; CULTURE MEDIUM; LUNG; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; L-SELECTIN; LIGANDS; LUNG; LUNG NEOPLASMS; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOPONTIN;

EID: 84900414577     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.132076     Document Type: Article

References (57)

1. Siegel R, Naishadham D, and Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin 63, 11-30.
2. Chambers AF, Groom AC, and MacDonald IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
3. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, and Gelmon K (2010). Metastatic behavior of breast cancer subtypes. J Clin Oncol 28, 3271-3277.
4. Nguyen DX, Bos PD, and Massagué J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274-284.
5. Ewing J (1928). Neoplastic Diseases. A Treatise on Tumors. WB Saunders Co, London, United Kingdom. pp. 77-89.
6. Paget S (1889). The distribution of secondary growths in cancer of the breast. The Lancet 1, 99-101.
7. Weiss L (1992). Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis 10, 191-199.
8. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009.
9. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, and Massagué J (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
10. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, and Massagué J (2005). Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.
11. Weiss L (1990). Metastatic inefficiency. Adv Cancer Res 54, 159-211.
12. Croker AK and Allan AL (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12, 374-390.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, and Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988.
14. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567.
15. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, et al. (2009). Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69, 1302-1313.
16. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, and Allan AL (2009). High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13, 2236-2252.
17. Croker AK and Allan AL (2012). Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat 133, 75-87.
18. Cailleau R, Olivé M, and Cruciger QV (1978). Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14, 911-915.
19. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, and Ethier SP (1999). Molecular cytogenetic analysis of 11 new breast cancer cell lines. Brit J Cancer 81, 1328-1334.
20. Price JE, Polyzos A, Zhang RD, and Daniels LM (1990). Tumorigenicity andmetastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50, 717-721.
21. Zhou YW, Aritake S, Tri Endharti A, Wu J, Hayakawa A, Nakashima I, and Suzuki H (2003). Murine lymph node-derived stromal cells effectively support survival but induce no activation/proliferation of peripheral resting T cells in vitro. Immunology 109, 496-503.
22. Lee J, Kuroda S, Shichinohe H, Ikeda J, Seki T, Hida K, Tada M, Sawada K, and Iwasaki Y (2003). Migration and differentiation of nuclear fluorescencelabeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice. Neuropathology 23, 169-180.
23. Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB, and Denhardt DT (2005). Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 22, 663-673.
24. Hammerschmidt SI, Ahrendt M, Bode U, Wahl B, Kremmer E, Förster R, and Pabst O (2008). Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med 205, 2483-2490.
25. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, and Horwitz E (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
26. Baddoo M, Hill K, Wilkinson R, Gaupp D, Hughes C, Kopen GC, and Phinney DG (2003). Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem 89, 1235-1249.
27. Singh B, Berry JA, Shoher A, Ramakrishnan V, and Lucci A (2005). COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26, 1393-1399.
28. Tuck AB, Chambers AF, and Allan AL (2007). Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102, 859-868.
29. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, and Massagué J (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770.
30. Hanley WD, Burdick MM, Konstantopoulos K, and Sackstein R (2005). CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 65, 5812-5817.
31. Hanley WD, Napier SL, Burdick MM, Schnaar RL, Sackstein R, and Konstantopoulos K (2006). Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J 20, 337-339.
32. Laubli H and Borsig L (2010). Selectins as mediators of lung metastasis. Cancer Microenviron 3, 97-105.
33. Naor D, Nedvetzki S, Golan I, Melnik L, and Faitelson Y (2002). CD44 in cancer. Crit Rev Clin Lab Sci 39, 527-579.
34. Chu JE and Allan AL (2012). The role of cancer stem cells in the organ tropism of breast cancer metastasis: a mechanistic balance between the "seed" and the "soil"? Int J Breast Cancer 2012, 209748.
35. Mastro AM and Vogler EA (2009). A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res 69, 4097-4100.
36. Horak E, Darling DL, and Tarin D (1986). Analysis of organ-specific effects on metastatic tumor formation by studies in vitro. J Natl Cancer Inst 76, 913-922.
37. Martin MD, Fingleton B, Lynch CC, Wells S, McIntyre JO, Piston DW, and Matrisian LM (2008). Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth. Clin Exp Metastasis 25, 877-885.
38. Bal de Kier Joffé E, Alonso DF, and Puricelli L (1991). Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells. Clin Exp Metastasis 9, 51-56.
39. Puricelli L, Gómez DE, Vidal MC, Eiján AM, Spinelli O, Alonso DF, de Lustig ES, and Bal de Kier Joffé E (1994). Effect of host-organ environment on the in vivo and in vitro behavior of a murine mammary adenocarcinoma. Tumour Biol 15, 284-293.
40. Chen Q, Zhang XH, and Massagué J (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538-549.
41. Roussos ET, Condeelis JS, and Patsialou A (2011). Chemotaxis in cancer. Nat Rev Cancer 11, 573-587.
42. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, et al. (2011). CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11, 418.
43. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, and Park JW (2003). Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIIIoverexpressing tumor cells. Cancer Res 63, 3154-3161.
44. Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E, and Peiró G (2014). Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triplenegative/ basal-like breast carcinomas subtypes and recurrence. Hum Pathol 45, 504-512.
45. Williams K, Motiani K, Giridhar PV, and Kasper S (2013). CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 238, 324-338.
46. Ma I and Allan AL (2011). The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7, 292-306.
47. Adams LS, Kanaya N, Phung S, Liu Z, and Chen S (2011). Whole blueberry powder modulates the growth and metastasis of MDA-MB-231 triple negative breast tumors in nude mice. J Nutr 141, 1805-1812.
48. Lowes LE, Goodale D, Keeney M, and Allan AL (2011). Image cytometry analysis of circulating tumor cells. Methods Cell Biol 102, 261-290.
49. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, and Sterling JA (2011). TGF-β promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 71, 822-831.
50. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, and Chambers AF (2011). Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9, 834-844.
51. Flanagan L, Van Weelden K, Ammerman C, Ethier SP, and Welsh J (1999). SUM-159PT cells: a novel estrogen independent human breast cancer model system. Breast Cancer Res Treat 58, 193-204.
52. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, and Lucci A (2010). Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27, 233-240.
53. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, et al. (2006). Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169, 233-246.
54. Hammerschmidt SI, Ahrendt M, Bode U, Wahl B, Kremmer E, Förster R, and Pabst O (2008). Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med 205, 2483-2490.
55. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, and Horwitz E (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
56. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, and Allan AL (2009). High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13, 2236-2252.
57. Croker AK and Allan AL (2012). Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat 133, 75-87.